Yusuke Nakamura to T-Lymphocytes, Cytotoxic
This is a "connection" page, showing publications Yusuke Nakamura has written about T-Lymphocytes, Cytotoxic.
Connection Strength
1.778
-
Identification of cytotoxic T cells and their T cell receptor sequences targeting COVID-19 using MHC class I-binding peptides. J Hum Genet. 2022 Jul; 67(7):411-419.
Score: 0.188
-
Neoantigens elicit T cell responses in breast cancer. Sci Rep. 2021 06 30; 11(1):13590.
Score: 0.181
-
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367.
Score: 0.145
-
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 01; 66(1):17-24.
Score: 0.131
-
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One. 2014; 9(1):e85267.
Score: 0.108
-
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012 Jul 09; 10:141.
Score: 0.097
-
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol. 2012 Jul; 42(7):591-600.
Score: 0.096
-
Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
Score: 0.092
-
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
Score: 0.088
-
The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010 May 01; 126(9):2153-63.
Score: 0.083
-
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer. 2008 Dec 01; 123(11):2616-25.
Score: 0.076
-
Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15; 10(24):8577-86.
Score: 0.057
-
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 2004 Dec 15; 10(24):8630-40.
Score: 0.057
-
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
Score: 0.037
-
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
Score: 0.036
-
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
Score: 0.034
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.033
-
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res. 2014 Aug; 34(8):4201-5.
Score: 0.028
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.027
-
Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013 Aug 15; 19(16):4508-20.
Score: 0.026
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
Score: 0.024
-
Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol. 2012; 2012:848042.
Score: 0.024
-
Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer. 2010 Sep 01; 127(6):1393-403.
Score: 0.021
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010 Feb; 101(2):433-9.
Score: 0.020
-
Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008 Oct 15; 14(20):6487-95.
Score: 0.019
-
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
Score: 0.018
-
Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May; 97(5):411-9.
Score: 0.016
-
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004 Oct 01; 10(19):6437-48.
Score: 0.014